AstraZeneca PLC
AZN
$89.10
$0.490.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.52% | 15.00% | 15.48% | 18.03% | 13.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.52% | 15.00% | 15.48% | 18.03% | 13.81% |
| Cost of Revenue | 9.36% | 24.49% | 23.40% | 28.02% | 87.93% |
| Gross Profit | 14.47% | 12.99% | 13.80% | 15.91% | 4.36% |
| SG&A Expenses | 5.71% | 8.68% | 8.77% | 11.72% | 2.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -41.89% | 5.99% | 75.88% | 81.25% | 78.34% |
| Total Operating Expenses | 9.51% | 15.15% | 16.89% | 20.28% | 23.34% |
| Operating Income | 27.65% | 14.49% | 10.72% | 10.28% | -10.58% |
| Income Before Tax | 44.40% | 29.40% | 24.96% | 25.97% | 16.84% |
| Income Tax Expenses | 43.11% | 32.28% | 37.36% | 75.91% | 62.33% |
| Earnings from Continuing Operations | 44.68% | 28.81% | 22.80% | 18.12% | 10.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | -40.00% | -66.67% | 0.00% | 37.50% |
| Net Income | 44.71% | 28.80% | 22.76% | 18.14% | 10.16% |
| EBIT | 27.65% | 14.49% | 10.72% | 10.28% | -10.58% |
| EBITDA | 17.63% | 14.33% | 11.36% | 11.06% | -4.36% |
| EPS Basic | 44.61% | 28.72% | 22.72% | 18.12% | 10.16% |
| Normalized Basic EPS | 30.29% | 16.38% | 12.74% | 11.64% | -11.68% |
| EPS Diluted | 44.97% | 28.81% | 22.35% | 17.74% | 9.61% |
| Normalized Diluted EPS | 30.37% | 16.42% | 12.72% | 11.61% | -11.74% |
| Average Basic Shares Outstanding | 0.06% | 0.06% | 0.03% | 0.02% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.05% | 0.06% | 0.05% | 0.06% |
| Dividend Per Share | 5.39% | 5.39% | 6.90% | 6.90% | 2.41% |
| Payout Ratio | -0.26% | -0.14% | -0.10% | -0.13% | -0.06% |